Users of the popular weight loss drug Ozempic are reportedly experiencing a new and unexpected side effect, now being referred to as “Ozempic teeth”. The term covers a range of dental problems such as dry mouth, bad breath, gum disease, and tooth decay.
According to the Daily Mail, experts have linked these issues to reduced saliva production, which may be a consequence of the drug’s appetite-suppressing effects. Ozempic, originally developed to treat type 2 diabetes, has become widely known for its role in supporting weight loss. However, the reduction in food intake that often accompanies its use may affect oral health.
Cosmetic dermatologist Dr Michele Green explained that eating stimulates the salivary glands, which helps protect teeth. “Saliva is crucial for protecting teeth, as it helps remove food particles, neutralises acids produced by bacteria in the mouth, and provides essential minerals that strengthen tooth enamel. When saliva levels are insufficient, the risk of cavities and tooth decay significantly increases,” she said.
Dr Green added that anecdotal evidence suggests Ozempic and similar drugs may contribute to dry mouth by limiting saliva production, thereby impairing the mouth’s natural ability to clean itself.
Further complications arise from some of the more common side effects of the drug, such as nausea, vomiting, and diarrhoea. Dentist Dr Victoria Holden told The Independent that vomiting poses serious risks to dental health due to stomach acid. “The stomach is very acidic, and if the patients are having that acid come up into their mouth, then it really is quite damaging to the teeth,” she said.
Dr Holden noted that Ozempic slows digestion, meaning food remains in the stomach for longer, which can lead to acid reflux. The resulting exposure of teeth to stomach acid can accelerate enamel erosion and other dental problems. She recommended consulting a medical professional if acid reflux occurs, warning that repairing acid damage to teeth can be both complex and costly.
Another concern linked to reduced food intake is nutritional deficiency. Dr Holden explained that insufficient nutrients could further impact oral health, contributing to discomfort and increasing the risk of dental issues.
“Ozempic teeth” is the latest in a series of terms coined to describe side effects associated with the drug. Others include “Ozempic mouth”, which involves changes in the appearance of the lips and surrounding skin, such as wrinkles, folds at the mouth’s corners, and sagging along the jawline.
Additionally, the term “Ozempic face” has been used to describe the prematurely aged look that some patients develop after rapid weight loss, often marked by gauntness and loss of volume in the face. “Ozempic butt” refers to the sagging of the rear area due to fat loss.
While Ozempic has proved effective for many in managing weight, these emerging side effects are prompting calls for more awareness about the broader impacts of the medication. Medical experts continue to advise users to discuss potential risks with healthcare providers before beginning or continuing treatment.
A milk product sold in Northern Ireland has been urgently recalled due to fears of contamination with a potentially deadly strain of E. coli bacteria. Kenneth Hanna's Farm Shop has issued a recall for its Ken's Raw Jersey Milk following the possible detection of Shiga toxin-producing Escherichia coli (STEC), a dangerous form of the bacteria.
The recall applies to all batch codes and use-by dates of the two-litre bottles sold in Northern Ireland. Consumers have been advised not to consume the product. Instead, the milk should either be returned to the place of purchase or safely disposed of.
The Food Standards Agency (FSA) has issued a public health warning, stating: “The possible presence of STEC in this product. Symptoms caused by STEC organisms include severe diarrhoea (including bloody diarrhoea), abdominal pain, and sometimes haemolytic uraemic syndrome (HUS), a serious condition that can lead to kidney failure and can be fatal.”
STEC is a specific strain of E. coli that produces Shiga toxins, which are capable of causing serious illness. One of the most recognised strains is E. coli O157:H7, commonly linked to foodborne outbreaks associated with undercooked meat, unwashed produce, and unpasteurised dairy products.
Symptoms of an STEC infection typically develop within three to four days of exposure but can appear anytime between one and ten days. They include stomach cramps, diarrhoea—often bloody—and in some cases, fever. These symptoms may last for up to two weeks. While many recover without complications, the infection can result in severe outcomes in certain individuals.
One of the most serious complications is haemolytic uraemic syndrome (HUS), which affects approximately 5 to 10 percent of STEC cases. HUS primarily impacts young children and the elderly, and symptoms include reduced urination, pale skin, fatigue, swelling, and unexplained bruising. In severe cases, the condition can lead to kidney failure and, in rare instances, death.
The FSA has advised anyone experiencing these symptoms to stay at home and avoid attending work, school, or nursery until they have been symptom-free for at least 48 hours to minimise the risk of spreading the infection.
The recall also sheds light on the ongoing debate around raw milk consumption. Ken's Raw Jersey Milk is an unpasteurised product, meaning it has not undergone the heat treatment process used to eliminate harmful bacteria. While supporters of raw milk claim it offers health benefits such as improved digestion and a richer nutrient profile, health authorities continue to warn of the risks associated with its consumption.
Raw milk can carry pathogens including E. coli, STEC, Listeria, and Salmonella. These bacteria are typically destroyed during pasteurisation, a process not applied to raw milk products.
This incident serves as a reminder of the potential dangers of consuming unpasteurised dairy. The FSA continues to monitor the situation, and consumers in Northern Ireland are urged to heed the recall notice and take appropriate safety precautions.
For further updates or health advice, consumers are encouraged to consult the FSA’s official website or contact their healthcare provider if symptoms appear.
Covid-19 cases are rising once again across several parts of the world, driven by the spread of the JN.1 variant – a new sub-lineage of Omicron known for its high transmissibility. While symptoms remain mostly mild, the latest spike has prompted health authorities in multiple countries to issue fresh public health advisories.
Cases are rising across Asia
Singapore has seen a sharp increase in cases, with 14,200 infections reported in the week ending 3 May, up from 11,100 the previous week. Hospital admissions also rose to an average of 133 per day, though the number of patients requiring intensive care fell slightly from three to two daily.
Hong Kong’s Centre for Health Protection described current virus activity as “quite high”, with the city recording its highest rate of respiratory samples testing positive in over a year. Authorities are monitoring the situation closely.
In Thailand, the latest surge is mostly affecting people aged 30 to 39, with health experts warning of more cases in the coming weeks. China, too, is experiencing a resurgence, although official figures remain limited.
India reports a modest increase
India has also recorded a slight uptick in Covid-19 cases. As of 19 May, the country had 257 active infections, with Kerala reporting the highest number (69), followed by Maharashtra (44) and Tamil Nadu (34). According to experts, most cases remain mild and do not require hospitalisation.
Health officials say the rise is partly due to the spread of the JN.1 variant, a drop in population-level immunity, and seasonal factors affecting people’s health. The increase in international travel is also believed to be contributing to the current wave.
What is the JN.1 variant?
The JN.1 variant has been labelled a “variant of interest” by global health bodies because of how quickly it spreads. Its symptoms include fever, sore throat, fatigue and mild respiratory issues. However, the severity of illness appears to remain low, particularly among those who have been vaccinated.
The variant has not been linked to increased hospital admissions or deaths, but public health authorities continue to urge caution.
Global health response
Authorities in affected countries are encouraging people to wear masks in crowded spaces, practise good hand hygiene, and stay home if they experience symptoms. While lockdowns and strict restrictions are not currently being considered, local measures could be introduced if hospital pressures increase.
In response to the broader pandemic preparedness challenge, the World Health Organisation recently adopted a historic Pandemic Agreement. The new framework aims to improve global cooperation and ensure a more equitable response to future pandemics, particularly in low- and middle-income countries.
As the world continues to navigate waves of Covid-19, experts are reminding the public not to become complacent. With new variants likely to emerge, maintaining basic precautions remains crucial in preventing further spread.
Keep ReadingShow less
The virus is transmitted via the bird-biting mosquitoes from Britain
The presence of West Nile virus has been detected in mosquitoes in the UK, health officials said. The UK Health Security Agency (UKHSA) has stated that the general public faces a “very low” risk from the virus, although it can cause serious illness in rare cases.
Authorities said there is currently no evidence of further spread of the virus among mosquito populations.
West Nile virus is transmitted through mosquito bites. The virus, spread by bird-biting mosquitoes, has become increasingly common in various parts of the world, including mainland Europe.
Mosquitoes and the diseases they carry are influenced by environmental factors such as climate change, which is pushing such risks further north. Aedes vexans mosquitoes, which are native to Britain, are among the species migrating along with vector-borne diseases as temperatures rise.
Only seven cases of West Nile virus have been reported in the UK since 2000, all linked to travel abroad. No cases have been acquired within the UK.
The virus regularly causes outbreaks in regions including parts of Africa, Asia, South America and Europe — a trend that has grown over time.
A 2023 research programme conducted by UKHSA and the Animal and Plant Health Agency (APHA) identified the virus in mosquitoes collected from ponds near Retford, Nottinghamshire.
“While this is the first detection of West Nile virus in mosquitoes in the UK, it is not unexpected as the virus is already widespread in Europe,” said Dr Meera Chand, Deputy Director for Travel Health and Infections at UKHSA.
Dr Arran Folly, who led the research programme, said the finding reflects “a wider changing landscape, where, in the wake of climate change, mosquito-borne diseases are expanding to new areas”.
West Nile virus-carrying mosquitoes typically breed in standing water. Health experts recommend using insect repellents and bed nets, and eliminating standing water sources, to help prevent transmission.
The virus often causes mild or no symptoms, making it difficult to detect. Common symptoms include headaches, high fever and skin rashes. In severe cases, the infection can be fatal. Last year, protests were held in Seville, Spain, after five people died from the virus.
Keep ReadingShow less
The vaccine will be offered through local authority-commissioned sexual health services
England is set to become the first country in the world to introduce a national gonorrhoea vaccination programme, in a move hailed by health officials as a “landmark moment for sexual health”. The rollout will begin on 1 August 2025 and will use an existing meningitis B vaccine, known as 4CMenB, to help combat soaring cases of gonorrhoea and growing concerns over antibiotic resistance.
The sexually transmitted infection (STI) reached record levels in England in 2023, with more than 85,000 cases reported — the highest number since records began in 1918. Health experts have warned that strains of the bacteria responsible for gonorrhoea, neisseria gonorrhoeae, are becoming increasingly resistant to current treatments.
The 4CMenB vaccine is currently used in the NHS childhood immunisation programme to protect against meningococcal group B disease, which can lead to serious conditions such as meningitis and sepsis. It is routinely administered to babies at eight weeks, 16 weeks, and one year of age. The vaccine contains proteins from neisseria meningitidis, a bacterium closely related to the gonorrhoea-causing strain, and has shown moderate effectiveness against gonorrhoea in clinical studies.
Research conducted by the Joint Committee on Vaccination and Immunisation (JCVI) estimates that the 4CMenB jab could provide between 32.7% and 42% protection against gonorrhoea. While it is not expected to completely prevent infection, experts say it significantly reduces the risk and offers vital protection, particularly for groups most at risk.
Dr Amanda Doyle, national director for primary care and community services at NHS England, said: “The launch of a world-first routine vaccination for gonorrhoea is a huge step forward for sexual health. It will be crucial in protecting individuals, helping to prevent the spread of infection, and reducing the rising rates of antibiotic-resistant strains of the bacteria.”
The vaccine will be offered through local authority-commissioned sexual health services, with eligible individuals identified and contacted in the coming weeks. At their appointment, patients will also be offered vaccinations for mpox (previously known as monkeypox), human papillomavirus (HPV), and hepatitis A and B.
Computer illustration of neisseria gonorrhoeaeAlamy
Gonorrhoea is currently the second most common bacterial STI in the UK. Symptoms may include green or yellow discharge from the genitals, pain while urinating, and rectal discomfort. Women may also experience lower abdominal pain or bleeding between periods. However, many people with the infection do not display any symptoms, increasing the risk of undetected transmission.
The new programme is being introduced amid warnings over rising resistance to ceftriaxone, the antibiotic most commonly used to treat gonorrhoea. In some cases, the bacteria have developed the ability to survive and multiply even after exposure to the drug. There is also growing concern about the emergence of extensively drug-resistant (XDR) strains — those which do not respond to ceftriaxone or second-line treatments.
According to the UK Health Security Agency (UKHSA), 17 cases of ceftriaxone-resistant gonorrhoea were recorded between January 2024 and March 2025, alongside nine XDR cases. This marks an increase from the five XDR cases reported between 2022 and 2023.
Dr Sema Mandal, consultant epidemiologist and deputy director at UKHSA, welcomed the vaccine rollout. “Not only will this rollout provide much-needed protection to those that need it most, but it will make the UK the first country in the world to offer this protection and a world leader in protecting people against gonorrhoea,” she said.
Health minister Ashley Dalton also urged eligible individuals to take up the offer of vaccination. “By targeting those most at risk, we can reduce transmission rates from this unpleasant disease that is becoming harder to treat and prevent thousands of cases over the next few years,” she said. “Getting vaccinated is not only about keeping yourself safe but also about helping tackle the growing threat of antibiotic resistance.”
The JCVI has previously highlighted that, unlike other infections, previous episodes of gonorrhoea offer little to no immunity against reinfection, making vaccination an important preventative step.
Richard Angell, chief executive of the sexual health charity Terrence Higgins Trust, called the jab a “gamechanger”, estimating that it could reduce new gonorrhoea cases by as much as 40%. He added, “This is a significant step forward in the fight against STIs and antimicrobial resistance. We encourage everyone eligible to come forward and get protected.”
NHS England is currently coordinating with local health teams to prepare for the rollout and ensure the new programme is fully operational from the start of August.
Keep ReadingShow less
Her journey reflects the challenges many international healthcare workers face
A nurse from Kerala who has worked to support fellow Malayali professionals in the UK has been invited to attend King Charles III’s garden party at Buckingham Palace in recognition of her contributions to the NHS and international nursing community.
Prabin Baby, 45, who currently works as a patient experience nurse in Hertfordshire, received the invitation in acknowledgement of her efforts to help internationally trained nurses, particularly from Kerala, integrate into the British healthcare system.
Originally from Tiruvalla, Kerala, Prabin moved to the UK in 2020 at the height of the COVID-19 pandemic. Despite her experience in Malaysia and India, including roles in clinical care and nursing education, she initially struggled to adapt to the NHS system. This personal challenge motivated her to assist others facing similar difficulties.
“When I arrived in the UK, I felt uncomfortable, despite having clinical experience and the required OET qualification,” Prabin said. “Internationally trained nurses face barriers in understanding the system. They need support, both professionally and culturally, to settle in. I believe someone has to step up and help.”
She joined Lister Hospital in Stevenage as a registered nurse before being promoted to educational and corporate roles within the East and North Hertfordshire NHS Trust. Through her work, she has supported the welfare and development of Malayali nurses, helping them to understand the NHS structure, workplace culture, and career development pathways.
Her professional growth was further supported by a fellowship with the Florence Nightingale Foundation Academy, which provided her with opportunities to develop her leadership skills and expand her work in supporting internationally educated staff. The NHS also funded her professional nurse advocate course, enhancing her ability to guide others in similar roles.
“I have always believed in collaboration with leadership to build an inclusive and supportive environment,” Prabin said. “Our trust is diverse and inclusive, and although there are many native English staff, I was honoured to be selected to attend the garden party.”
Speaking about the event at Buckingham Palace, Prabin said she felt proud and humbled as an Indian nurse. “There were times when I stood outside the palace and wondered what it was like inside. To have the opportunity to enter and meet the royals and others who have contributed to public service was a memorable experience.”
She credited her family—her daughter, parents and sister—for their continuous support. “They are my backbone and have always encouraged me in my work.”
Prabin also highlighted the broader professional opportunities available to nurses in the UK. “If we are interested and willing to learn, there is much scope to specialise and progress here. The recognition and appreciation we receive are often greater than in India or other developed countries.”
Her journey reflects the challenges many international healthcare workers face and the importance of mentorship, institutional support and inclusive leadership within the NHS.